Drug-resistant tuberculosis: Difference between revisions

From IDWiki
mNo edit summary
Β 
(5 intermediate revisions by the same user not shown)
Line 1: Line 1:
== Background ==
* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and rifampin
* [[Mycobacterium tuberculosis]] infection that is resistant to both first-line drugs, isoniazid and [[rifampin]]


== Classification ==
=== Classification ===
* '''Multidrug resistant tuberculosis (MDR-TB)''': resistance to [[isoniazid]] and [[rifampicin]]
* '''Multidrug resistant tuberculosis (MDR-TB)''': resistance to [[isoniazid]] and [[rifampicin]]
** Rifampin monoresistance is quite rare, so MDR is usually inferred from rifampin resistance alone
* '''Extensively drug-resistant tuberculosis (XDR-TB)''': resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
* '''Extensively drug-resistant tuberculosis (XDR-TB)''': resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
* '''Totally drug-resistant tuberculosis (TDR-TB)''': not well-defined
* '''Totally drug-resistant tuberculosis (TDR-TB)''': not well-defined

=== Resistance Mechanisms ===

* 90% of isoniazid resistance is from known mutations in either the katG or InhA genes
* 95% of rifampin resistance is from known mutations in the rpoB gene

=== Risk Factors ===

* The strongest predictor of MDR-TB is prior TB treatment (increases from 3% to 18% of cases)
* Residence in country with higher rate of MDR-TB: India (8%/13% new/previous treatment), Philippines (12%/15%), China (7%/8%), Viet Nam (14%/10%), Pakistan (8%/7%), Ethiopia (6%/13%), Somalia (6%/8%), Haiti (unclear), Hong Kong (5%/7%), Afghanistan (unclear)
* Exposure to person with MDR-TB
* HIV infection
* Other risk factors include younger age and more recent arrival from endemic country


== Management ==
== Management ==
* '''Rapid PCR testing for rifampin resistance''' should be considered in all patients, but definitely done if at increased risk of MDR-TB
⚫
* 8 months of an intensive four-drug regimen that includes any four drugs to which it is susceptible, in order of preference:
* Referral to a specialized TB program
** Any first-line agents to which it is still susceptible
* First-line is generally a [[Fluoroquinolones|fluoroquinolone]], [[bedaquiline]], [[linezolid]], [[clofazimine]], and [[cycloserine]]
** A fluoroquinolone (except ciprofloxacin)
⚫
* Other regimens are any five drugs to which it is susceptible, in order of preference:
** An injectable: kanamycin, or other parenteral agent
** Group A: [[fluoroquinolones]] (except [[ciprofloxacin]]), [[bedaquiline]], [[linezolid]]
** Other second-line agents, starting with ethionamide
** Group B: [[clofazimine]], [[cycloserine]] (or [[terizidone]])
* Followed by 12 months of a less intensive regimen (at least three effective drugs), for a total of at least 20 months
** Group C: [[ethambutol]], [[pyrazinamide]], [[delamanid]], [[amikacin]] (or [[streptomycin]]), [[imipenem-cilastatin]] (or [[meropenem)]], [[ethionamide]], [[p-aminosalicylic acid]]
* For low-burden disease, can consider a 4-drug regimen
* Duration
** Intensive phase (5 drugs) of 5 and 7 months after culture conversion, followed by consolidation phase with 4 drugs
** Total treatment duration between 15 and 21  months after culture conversion

=== BPaLM ===


* [[Bedaquiline]], [[pretomanid]], [[linezolid]], and [[moxifloxacin]] (BPaLM) for 6 months[[CiteRef::nyang’wa2022a]] now [https://www.who.int/publications/i/item/9789240065116 recommended by WHO]
* Should be avoided in CNS disease, disseminated TB, children, or pregnant patients

=== Specific Resistance Patterns ===
{| class="wikitable"
{| class="wikitable"
!Resistance To
!Resistance To
!Replace With
!Drug to Stop
!Drug to Add
!Regimen
!Regimen
!Total Duration
!Total Duration
|-
|-
|INH
|INH
|INH
|FQN
|FQN
Line 27: Line 51:
|6 months from date FQN started
|6 months from date FQN started
|-
|-
|INH
|INH
|INH
|FQN
|FQN
Line 33: Line 56:
|6 months from date FQN started
|6 months from date FQN started
|-
|-
|RMP
|RMP
|RMP
|FQN
|FQN
Line 39: Line 61:
|18 months from date FQN started
|18 months from date FQN started
|-
|-
|RMP
|RMP
|RMP
|None
|None
Line 45: Line 66:
|18 months from date FQN started
|18 months from date FQN started
|-
|-
|EMB
|EMB
|EMB
|None
|None
Line 51: Line 71:
|6 months from start of therapy
|6 months from start of therapy
|-
|-
|PZA
|PZA
|PZA
|None
|None
Line 57: Line 76:
|9 months from start of therapy
|9 months from start of therapy
|-
|-
|INH+EMB
|INH+EMB
|INH+EMB
|FQN
|FQN
Line 63: Line 81:
|6 months from date FQN started
|6 months from date FQN started
|-
|-
|INH+PZA
|INH+PZA
|INH+PZA
|FQN
|FQN
Line 69: Line 86:
|9 months from date FQN started
|9 months from date FQN started
|-
|-
|INH+EMB+PZA
|INH+EMB+PZA
|INH+EMB+PZA
|FQN+injectable
|FQN+injectable
Line 75: Line 91:
|9 months from date FQN started
|9 months from date FQN started
|}
|}
*


[[Category:Tuberculosis]]
[[Category:Tuberculosis]]

Latest revision as of 17:39, 19 September 2024

Background

Classification

  • Multidrug resistant tuberculosis (MDR-TB): resistance to isoniazid and rifampicin
    • Rifampin monoresistance is quite rare, so MDR is usually inferred from rifampin resistance alone
  • Extensively drug-resistant tuberculosis (XDR-TB): resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables
  • Totally drug-resistant tuberculosis (TDR-TB): not well-defined

Resistance Mechanisms

  • 90% of isoniazid resistance is from known mutations in either the katG or InhA genes
  • 95% of rifampin resistance is from known mutations in the rpoB gene

Risk Factors

  • The strongest predictor of MDR-TB is prior TB treatment (increases from 3% to 18% of cases)
  • Residence in country with higher rate of MDR-TB: India (8%/13% new/previous treatment), Philippines (12%/15%), China (7%/8%), Viet Nam (14%/10%), Pakistan (8%/7%), Ethiopia (6%/13%), Somalia (6%/8%), Haiti (unclear), Hong Kong (5%/7%), Afghanistan (unclear)
  • Exposure to person with MDR-TB
  • HIV infection
  • Other risk factors include younger age and more recent arrival from endemic country

Management

BPaLM

Specific Resistance Patterns

Resistance To Replace With Regimen Total Duration
INH FQN 6 months RMP+EMB+PZA+FQN 6 months from date FQN started
INH FQN 2 months RMP+EMB+PZA+FQN then 4 months RMP+EMB+FQN 6 months from date FQN started
RMP FQN 2 months daily INH+EMB+PZA+FQN then 10-16 months INH+EMB+FQN 18 months from date FQN started
RMP None 2 months INH+EMB+PZA, then 16 months INH+EMB 18 months from date FQN started
EMB None 2 months INH+RMP+PZA, then 4 months INH+RMP 6 months from start of therapy
PZA None 2 months INH+RMP+EMB, then 7 months INH+RMP 9 months from start of therapy
INH+EMB FQN 6 months daily RMP+PZA+FQN 6 months from date FQN started
INH+PZA FQN 9 months RMP+EMB+FQN 9 months from date FQN started
INH+EMB+PZA FQN+injectable 2 months TMP+FQN+injectable, then 7 months RMP+FQN 9 months from date FQN started

References

  1. ^  Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, Ilaria Motta, Nargiza Parpieva, Zinaida Tigay, Varvara Solodovnikova, Irina Liverko, Ronelle Moodliar, Matthew Dodd, Nosipho Ngubane, Mohammed Rassool, Timothy D. McHugh, Melvin Spigelman, David A.J. Moore, Koert Ritmeijer, Philipp du Cros, Katherine Fielding. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine. 2022;387(25):2331-2343. doi:10.1056/nejmoa2117166.

Retrieved from "https://idwiki.org/index.php?title=Drug-resistant_tuberculosis&oldid=10706"
Powered by MediaWiki
Powered by Semantic MediaWiki